Клинические аспекты диагностики и лечения остеопороза у женщин в постменопаузе
- Авторы: Апетов С.С.1, Апетова В.В1
-
Учреждения:
- ООО «Центр эндокринного здоровья»
- Выпуск: Том 28, № 12 (2021)
- Страницы: 18-25
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/313291
- DOI: https://doi.org/10.18565/pharmateca.2021.12.18-25
- ID: 313291
Цитировать
Полный текст



Аннотация
Менопаузальный переход характеризуется ускоренной потерей костной массы, повышением риска деформаций скелета и низкоэнергетических переломов. Основной причиной постменопаузального остеопороза является стойкое снижение и прекращение эстроген-продуцирующей функции яичников. Клиницистам, которые занимаются проблемой остеопороза, следует помнить, что нельзя ставить знак равенства между терминами «постменопаузальный остеопороз» и «остеопороз у женщин в постменопаузе», т.к. у пациенток в постменопаузе могут быть другие заболевания и факторы, ускоряющие потерю минеральной плотности костной ткани, вызванную снижением уровня эстрогенов, тем самым повышая риск развития остеопороза и низкоэнергетических переломов (вторичный остеопороз).
Ключевые слова
Полный текст

Об авторах
Сергей Сергеевич Апетов
ООО «Центр эндокринного здоровья»
Email: apetov@rambler.ru
к.м.н., врач-эндокринолог, акушер-гинеколог Челябинск, Россия
В. В Апетова
ООО «Центр эндокринного здоровья»Челябинск, Россия
Список литературы
- URL: https://rosstat.gov.ru/compendium/document/13285
- Kristensen P.K., Perez-Vicente R., Leckie G., et al. Disentangling the contribution of hospitals and municipalities for understanding patient level differences in one-year mortality risk after hip-fracture: a cross-classified multilevel analysis in Sweden. PLoS One. 2020;15(6):e0234041. doi: 10.1371/journal.pone.0234041.
- Meyer I., Morgan S.L., Markiand A.D., et al. Peivic floor disorder symptoms and bone strength in postmenopausal women. Int Urogynecol J. 2020;31(9):1777-84. doi: 10.1007/s00192-020-04254-z.
- Curhan S.G., Stankovic K., Halpin C., et al. Osteoporosis, bisphosphonate use, and risk of moderate or worse hearing loss in women. J Am Geriatr Soc. 2021 May 24. Doi: 10.1111/ jgs.17275. Online ahead of print.
- Park J., Yoon YE., Kim K.M., et al. Prognostic value of lower bone mineral density in predicting adverse cardiovascular disease in Asian women. Heart. 2021 May 7: heartjnl-2020-318764. doi: 10.1136/heartjnl-2020-318764. Online ahead of print.
- Sumino H., Ichikawa S., Abe M., et al. Effects of aging and postmenopausal hypoestrogenism on skin elasticity and bone mineral density in Japanese women. Endocr J. 2004;51(2):159-64. doi: 10.1507/endocrj.51.159.
- Tomasevic-Todorovic S., Vazic A., et al. Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study.O pen Access Rheumatol. 2018;10:61-6. doi: 10.2147/OARRR.S151307.
- Wattanachanya L., Pongchaiyakul C. Prevalence and risk factors of morphometric vertebral fracture in apparently healthy osteopenic postmenopausal Thai women. Menopause. 2020;28(1):12-7. doi: 10.1097/GME.0000000000001634.
- Ji M.X., Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015;1(1):9-13. Doi: 10.1016/j. cdtm.2015.02.006.
- Santen R.J., Pinkerton J.V, Liu J.H., et al. Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. Menopause. 2020;27(6):614-doi: 10.1097/GME.0000000000001556.
- Singh P, Singh M., Khinda R., et al. Genetic Scores of eNOS, ACE and VEGFA Genes Are Predictive of Endothelial Dysfunction Associated Osteoporosis in Postmenopausal Women. Int J Environ Res Public Health. 2021;18:972. Doi: 10.3390/ ijerph18030972.
- Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-11. Doi: 10.1056/ NEJM199906103402306.
- Watson E.C., Adams R.H. Biology of Bone: The Vasculature of the Skeletal System. Cold Spring Harb Perspect Med. 2018;8(7):031559. doi: 10.1101/cshperspect.a031559.
- Tomlinson R.E., Silva M.J. Skeletal Blood Flow in Bone Repair and Maintenance. Bone Res. 2013;1:311-22. doi: 10.4248/BR201304002.
- Marenzana M., Arnett T.R. The Key Role of the Blood Supply to Bone. Bone Res. 2013;1:203-215. doi: 10.4248/BR201303001
- Rucci N. Molecular biology of bone remodelling. Clin. Cases Miner. Bone Metab. 2008;5:49-56.
- Blum A., Zarqh O., Peleg A., et al. Vascular inflammation and endothelial dysfunction in fracture healing. Am J Orthop Belle Mead NJ. 2012;41:87-91.
- Zhao Y, Xie L. Unique bone marrow blood vessels couple angiogenesis and osteogenesis in bone homeostasis and diseases. Ann NY Acad Sci. 2020;1474:5-14. doi: 10.1111/nyas.14348.
- Finkelstein J.S, Brockwell S.E., Mehta V., et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93(3):861-68. doi: 10.1210/jc.2007-1876.
- Tella S.H., Gallagher J.C. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155-70. Doi: 10.1016/j. jsbmb.2013.09.008.
- Parfitt A.M. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res. 1982;4(1):1-6. doi: 10.1016/0221-8747(82)90002-9.
- Yoo J.E., Shin D.W., Han K., et al. Association of Female Reproductive Factors With Incidence of Fracture Among Postmenopausal Women in Korea. JAMA Netw Open. 2021;4(1):e2030405. doi: 10.1001/jamanetworkopen.2020.30405.
- Ahmeidat A., Bhattacharya S., Luben R.N., et al. Long-term effects of gestational diabetes on bone mineral density and fracture risk: Analysis of the Norfolk cohort of the European Prospective Invest.igat.ion into Cancer (EPIC-Norfolk) population-based study Maturitas. 2021;144:68-doi: 10.1016/j.maturitas.2020.11.005.
- Lee E.N. Effects of Parity and Breastfeeding Duration on Bone Density in Postmenopausal Women. Asian Nurs Res (Korean Soc Nurs Sci). 2019;13(2):161-doi: 10.1016/j.anr.2019.04.002.
- Polyzos S.A., Anastasilakis A.D., Efstathiadou Z.A., et al. Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. Maturitas 2021;147:19-25. Doi: 10.1016/j. maturitas.2021.02.007.
- Abbasi M., Farzam S.A., Mamaghani Z., Yazdi Z. Relationship between metabolic syndrome and its components with bone densitometry in postmenopausal women. Diabetes Metab Syndr. 2017;11(Suppl 1):S73-S76. Doi: 10.1016/j. dsx.2016.12.008.
- Caglayan E.K., Engin-Ustun Y, Sari N., et al. Evaluation of bone density measurement in type 2 diabetic postmenopausal women with hypertension and hyperlipidemia. J Menopausal Med. 2015;21(1):36-40. Doi: 10.6118/ jmm.2015.21.1.36.
- Turan E., Kizilkaya H., Aral Y. Is metabolic syndrome related to postmenopausal osteoporosis? A retrospective study. Arch Clin Exp Med 2018;3(2):71-4. doi: 10.25000/acem.419847.
- Seimon R.V, Wild-Taylor A.L., Keating S.E., et al. Effect of Weight Loss via Severe vs Moderate Energy Restriction on Lean Mass and Body Composition Among Postmenopausal Women With Obesity: The TEMPO Diet Randomized Clinical Trial. JAMA Netw Open. 2019;2(10):e1913733. Doi: 10.1001/ jamanetworkopen.2019.13733.
- Paschou S.A., Dede A.D., Anagnostis PG., et al. Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. J Clin Endocrinol Metab. 2017;102(10):3621-34. Doi: 10.1210/ jc.2017-00042.
- Leutner M., Matzhold C., Bellah L., et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann Rheum Dis. 2019;78:1706-11. doi: 10.1136/annrheumdis-2019-215714.
- Sugitani I., Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011;150(6):1250-57. Doi: 10.1016/j. surg.2011.09.013.
- Kwak D., Ha J., Won Y., et al. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open. 2021;11(5):e043007. Doi: 10.1136/ bmjopen-2020-043007.
- Percivale A., Gnerre P, Damonte G., et al. Primary hyperparathyroidism: epidemiology, clinical features, diagnostic tools and current management. Italian Journal of Medicine. 2015,9(4),330-45.
- Desai M.K., Brinton R.D. Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. Front Endocrinol (Lausanne). 2019;10:265. doi: 10.3389/fendo.2019.00265.
- Maldonado G., Messina O., Moreno M., Ros C. Osteoporosis in rheumatic diseases and glucocorticoid induced. Rev Osteoporos Metab Miner. 2017;9(1):38-49.
- Fardet L., Petersen I., Nazareth I. Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. Medicine (Baltimore). 2015;94(15):e647. doi: 10.1097/ MD.0000000000000647.
- Overman R.A., Yeh J.Y., Deal C.L. Prevalence of oral glucocortidoid usage in the United States: a general population perspective. Arthr Care Res. 2013;65:294-98. doi: 10.1002/acr.21796.
- Silverman S., Curtis J., Saag K., et al. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2015;26(1):419-20. doi: 10.1007/s00198-014-2883-2.
- Chotiyarnwong P, McCloskey E.V Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437-47. doi: 10.1038/s41574-020-0341-0.
- Triebner K., Matulonga B., Johannessen A., et al. Menopause Is Associated with Accelerated Lung Function Decline. Am J Respir Crit Care Med. 2017;195(8):1058-65. doi: 10.1164/ rccm.201605-0968OC.
- Swaminathan K., Flynn R., Garton M., et al. Search for secondary osteoporosis: are Z scores useful predictors? Postgrad Med J. 2009;85(999):38-9. doi: 10.1136/pgmj.2007.065748.
- Cauley J.A., Robbins J., Chen Z., et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290(: 3doi: 10.1001/jama.290.13.1729.
- Jackson R.D., Wactawski-Wende J., LaCroix A.Z., et al.; Women's Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006;21(6):817-28. doi: 10.1359/ jbmr.060312.
- Zhu L., Jiang X., Sun Y, Shu W. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause. 2016;23(4):461-70. doi: 10.1097/GME.0000000000000519.
- Silverstein W.K., Zipursky J.S., Shadowitz S. Closing the Osteoporosis Care Gap: A Teachable Moment. JAMA Intern Med. Published online October 18, 2021. doi: 10.1001/jamainternmed.2021.5972.
- Eastell R., Rosen C.J., Black D.M., et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. Doi: 10.1210/ jc.2019-00221.
- Vestergaard P. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int. 2011;89(4):265-70. Doi: 10.1007/ s00223-011-9515-z.
- Peng R., Liang X., Zhang G., et al. Association Use of Bisphosphonates with RiskofBreastCancer: A MetaAnalysis. Biomed Res Int. 2020;2020:5606573. doi: 10.1155/2020/5606573.
- Burt L.A., Billington E.O., Rose M.S., et al. Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males. J Bone Miner Res. 2020;35(12):2404-14. doi: 10.1002/jbmr.4152.
- Zarei A., Morovat A., Javaid K., Brown C.P Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts. Bone Res. 2016;4:16030. doi: 10.1038/boneres.2016.30.
- Bolland M.J., House M.E., Horne A.M., et al. Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. J Bone Miner Res. 6020;3-(4);1040-47.Doi: 10.1002/ jbmr.3982.
- El-Sergany M., Shahba A., Al-Ahwal L. Exercise versus Estrogen Therapy in Osteoporotic Postmenopausal Women with Endothelial Dysfunction. J Am Sci. 2010;6(10):1013-18.
Дополнительные файлы
